Timeline of the Covid-19 pandemic in Oxfordshire bicesteradvertiser.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bicesteradvertiser.net Daily Mail and Mail on Sunday newspapers.
331 shares Prostagram has the potential to form the basis of a fast, mobile national screening programme for prostate cancer and could be a game-changer, said senior study author Professor Hashim Ahmed, Chair of Urology at Imperial College London. Prostagram also has the potential to detect more aggressive cancers earlier and pass over the many cancers which don t need to be diagnosed. By finding these aggressive cancers at the earliest opportunity, men have the opportunity to be offered less invasive treatments with fewer side effects.
A landmark trial of Prostagram, involving 408 men, has been detailed in a paper published in Jama Oncology.
drugs already in the market. Scientists at Imperial College London (ICL) announced they would instead use the technology behind the vaccine to target
coronavirus mutations. “Although our first generation Covid-19 vaccine candidate is showing promise in early clinical development, the broader situation has changed with the rapid roll-out of approved vaccines,” Prof Robin Shattock at the department of medicine said.
“It is not the right time to start a new efficacy trial for a further vaccine in the UK, with the emphasis rightly placed on mass vaccination in response to the rapid spread of the new variant.”
The vaccines developed so far appear to be effective against mutations that
LONDON: Scientists at Imperial College London have abandoned testing of their coronavirus vaccine to focus on combating emerging variants of the virus detected around the world.
The decision comes as the scientific community scrambles to get ahead of the new threat, which could require updated inoculations.
Prof. Robin Shattock, head of the vaccine team at Imperial, said scientists will now use the ribonucleic acid (RNA) technology behind the initial vaccine to target new and emerging coronavirus variants.
“Although our first generation vaccine candidate is showing promise in early clinical development, the broader situation has changed with the rapid rollout of approved vaccines,” he said in a statement on Tuesday.